Test Id : IDCOR
Red Blood Cell Antigen Genotyping, PCR, Blood
Useful For
Suggests clinical disorders or settings where the test may be helpful
Determining the red blood cell status of any patient but more useful than serology in the following situations:
-Recently transfused patient.
-Patient with a positive direct antiglobulin test.
-Patient with a discrepant antigen typing with antibodies present.
This test is not useful for the purpose of:
-Establishing paternity
-Diagnosing McLeod syndrome or determining the McLeod phenotype
-Determining A1 subtype
Highlights
This test can be used to determine red blood cell genotype and predict the red blood cell phenotype. The following red cell antigens will be displayed in the final report:
C, E, c, e, CW, V, hrS, VS, hrB, K, k, Kpa, Kpb, Jsa, Jsb, Jka, Jkb, Fya, Fyb, M, N, S, s, U, Mia, Dia, Dib, Doa, Dob, Hy, Joa, Coa, Cob, Yta, Ytb, Lua, and Lub.
Method Name
A short description of the method used to perform the test
Molecular Genotyping
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
RBC Genotype
Molecular Genotype, RBC
Predicted Phenotype, RBC
Specimen Type
Describes the specimen type validated for testing
Whole Blood EDTA
Ordering Guidance
This test is used to determine red blood cell genotype and predict the phenotype. It does not determine the A1 phenotype subtype or aid in the diagnosis of McLeod syndrome.
-If testing for McLeod syndrome (phenotype) is desired, order SPAGR / Special Red Cell Antigen Typing, Whole Blood and note "K system antigens" on the order.
-If the A1 subtype is requested, order SPAGR and note "A1 antigen" on the order.
Shipping Instructions
1. Specimen must arrive within 7 days of collection.
2. Collect and package specimen as close to shipping time as possible.
Necessary Information
Pertinent clinical history, including whether the patient has received a bone marrow transplant, is required.
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Container/Tube:
Preferred: Pink top (EDTA)
Acceptable: Lavender top (EDTA)
Specimen Volume: 6 mL
Pediatric Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Label specimen as blood.
3. Send whole blood specimen in the original tube. Do not aliquot.
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
3 mL
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Gross hemolysis | OK |
| Gross lipemia | OK |
| Gross icterus | OK |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood EDTA | Refrigerated (preferred) | 7 days | |
| Ambient | 7 days |
Useful For
Suggests clinical disorders or settings where the test may be helpful
Determining the red blood cell status of any patient but more useful than serology in the following situations:
-Recently transfused patient.
-Patient with a positive direct antiglobulin test.
-Patient with a discrepant antigen typing with antibodies present.
This test is not useful for the purpose of:
-Establishing paternity
-Diagnosing McLeod syndrome or determining the McLeod phenotype
-Determining A1 subtype
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
The predicted red blood cell (RBC) phenotype will determine the presence or absence of an RBC antigen. As a general rule, individuals will not make an antibody directed against an antigen present on their own RBCs.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
The presence or absence of each red blood cell antigen is identified.
Interpretation
Provides information to assist in interpretation of the test results
Each antigen will be listed by name, followed by a "+" indicating the antigen is present, or by a "0" indicating the antigen is absent. Additional footnotes may be included indicating additional information is present along with the result.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Samples yielding low DNA concentration (<20 ng/mcL) that falls outside a DNA purity range (A260/A280) of 1.65 to 2.00 may not provide valid results. Additionally, the assay will not detect all variants of allele haplotypes.
Clinical Reference
Recommendations for in-depth reading of a clinical nature
1. Mouro I, Colin Y, Sistonen P, Le Pennec PY, Cartron JP, Le Van Kim C. Molecular basis of the RhCW (Rh8) and RhCX (Rh9) blood group specificities. Blood. 1995;86(3):1196-1201.
2. Doscher A, Vogt C, Bittner R, Gerdes I, Petershofen EK, Wagner FF. RHCE alleles detected after weak and/or discrepant results in automated Rh blood grouping of blood donors in Northern Germany. Transfusion. 2009;49(9):1803-1811. doi:10.1111/j.1537-2995.2009.02221.x
3. Doescher A, Wagner FF, Vogt C, Glameyer T, Petershofen EK. P-306: Three new polymorphisms in patients with serologic suspect of weakened expression of RHC-antigen. Vox Sang. 2005;89 (Suppl.1):159
4. Ochoa G, Nogues N, Muniz-Diaz E, et al. P-480: Association of altered E RHCE*cE(697G,712G,733G,744C) with altered D RHD*46C. Vox Sang. 2012;103 (Suppl.1):218
5. Goldman M, Cemborain A, Cote J, et al. Identification of six new RHCE variant alleles in individuals of diverse racial origin. Transfusion. 2016;56(1):244-248. doi:10.1111/trf.13357
6. Cherif-Zahar B, Raynal V, Cartron JP. Lack of RHCE-encoded proteins in the D--phenotype may result from homologous recombination between the two RH genes. Blood. 1996;88(4):1518-1520.
7. Mouro I, Colin Y, Cherif-Zahar B, Cartron JP, Le Van Kim C. Molecular genetic basis of the human Rhesus blood group system. Nat Genet. 1993;5(1):62-65. doi:10.1038/ng0993-62
8. Ochoa-Garay G, Moulds JM, Cote J, et al. New RHCE variant alleles encoding the D-?- phenotype. Transfusion. 2013;53(11 Suppl 2):3018-3023. doi:10.1111/trf.12404
9. Billingsley KL, Posadas JB, Moulds JM, Gaur LK. A novel JK null allele associated with typing discrepancies among African Americans. Immunohematology. 2013;29(4):145-148.
10. Bugert P, Scharberg EA, Geisen C, von Zabern I, Flegel WA. RhCE protein variants in Southwestern Germany detected by serologic routine testing. Transfusion. 2009;49(9):1793-1802. doi:10.1111/j.1537-2995.2009.02220.x
11. Noizat-Pirenne F, Mouro I, Gane P, et al. Heterogeneity of blood group RhE variants revealed by serological analysis and molecular alteration of the RHCE gene and transcript. Br J Haematol. 1998;103(2):429-436. doi:10.1046/j.1365-2141.1998.01004.x
12. Ekman GC, Hessner MJ. Screening of six racial groups for the intron 5 G-->A 3' splice acceptor mutation responsible for the polynesian kidd (a-b-) phenotype: the null mutation is not always associated with the JKB allele. Transfusion. 2000;40(7):888-889. doi:10.1046/j.1537-2995.2000.40070888.x
13. Zimmerman PA, Woolley I, Masinde GL, et al. Emergence of FY*A(null) in a Plasmodium vivax-endemic region of Papua New Guinea. Proc Natl Acad Sci U S A. 1999;96(24):13973-13977. doi:10.1073/pnas.96.24.13973
14. Lopez GH, Condon JA, Wilson B, et al. A novel FY*A allele with the 265T and 298A SNPs formerly associated exclusively with the FY*B allele and weak Fy(b) antigen expression: implication for genotyping interpretative algorithms. Vox Sang. 2015;108(1):52-57. doi:10.1111/vox.12185
15. Daniels G. Human Blood Groups. Wiley-Blackwell; 2013
16. Reid M, Lomas-Francis C, Olsson ML. The Blood Group Antigen Facts Book. 3rd ed. Academic Press; 2012
17. The International Society of Blood Transfusion (ISBT) Working Party for Red Cell Immunogenetics and Blood Group Terminology. Red cell immunogenetics and blood group terminology. ISBT; Revised October 2024. Accessed May 13, 2025. Available at www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology
18. Moller M, Joud M, Storry JR, Olsson ML. Erythrogene: a database for in-depth analysis of the extensive variation in 36 blood group systems in the 1000 Genomes Project. Blood Adv. 2016;1(3):240-249. Published 2016 Dec 16. doi:10.1182/bloodadvances.2016001867
19. RHCE Table. New York Blood Center Enterprises; 2025. Accessed May 14, 2025. Available at www.nybce.org/national-center-for-blood-group-genomics/rhce-table/
Method Description
Describes how the test is performed and provides a method-specific reference
The ID CORE XT assay utilizes Luminex xMAP technology. Genomic DNA extracted from human EDTA anticoagulated whole blood is amplified and biotinylated by multiplex polymerase chain reaction (PCR). PCR products are denatured and hybridized to oligonucleotide probes coupled to color-coded beads. Hybridized DNA is labeled with a fluorescent conjugate, and the resulting signal is detected with a Luminex 200 system. Raw data are processed with ID CORE XT analysis software to obtain benign alteration (previously polymorphism) genotypes, predicted allele genotypes, and predicted phenotypes for: C, E, c, e, CW, V, hrS, VS, hrB, K, k, Kpa, Kpb, Jsa, Jsb, Jka, Jkb, Fya, Fyb, M, N, S, s, U, Mia, Dia, Dib, Doa, Dob, Hy, Joa, Coa, Cob, Yta, Ytb, Lua, and Lub.(Package insert: ID CORE XT. Grifols; PI_1021720000_05, 01/2023)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday through Friday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
0084U
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| IDCOR | IDCORE XT RBC Genotype | 93914-0 |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| 623290 | IDCORE XT RBC Genotype | 906-8 |